Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

Paul J. Hengeveld; Y. Emre Ertem; Julie M. N. Dubois; Clemens H. M. Mellink; Anne-Marie van der Kevie-Kersemaekers; Ludo M. Evers; Kim Heezen; P. Martijn Kolijn; Olaf R. F. Mook; M. Mahdi Motazacker; Kazem Nasserinejad; S. Kersting; Peter E. Westerweel; Carsten U. Niemann; Arnon P. Kater; Anton W. Langerak; Mark-David Levin

doi:https://doi.org/10.1038/s41375-022-01600-6

Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

Paul J. Hengeveld, Y. Emre Ertem, Julie M. N. Dubois, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Ludo M. Evers, Kim Heezen, P. Martijn Kolijn, Olaf R. F. Mook, M. Mahdi Motazacker, Kazem Nasserinejad, S. Kersting, Peter E. Westerweel, Carsten U. Niemann, Arnon P. Kater, Anton W. Langerak, Mark-David Levin

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	1935-1938
Number of pages	4
Journal	Leukemia
Volume	36
Issue number	7
Early online date	2022
DOIs	https://doi.org/10.1038/s41375-022-01600-6
Publication status	Published - 1 Jul 2022

Access to Document

https://doi.org/10.1038/s41375-022-01600-6

Cite this

Hengeveld, P. J., Ertem, Y. E., Dubois, J. M. N., Mellink, C. H. M., van der Kevie-Kersemaekers, A.-M., Evers, L. M., Heezen, K., Kolijn, P. M., Mook, O. R. F., Motazacker, M. M., Nasserinejad, K., Kersting, S., Westerweel, P. E., Niemann, C. U., Kater, A. P., Langerak, A. W., & Levin, M.-D. (2022). Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110. Leukemia, 36(7), 1935-1938. https://doi.org/10.1038/s41375-022-01600-6

@article{3e6f01aab4c04799a51b272ba87c5425,

title = "Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110",

author = "Hengeveld, {Paul J.} and Ertem, {Y. Emre} and Dubois, {Julie M. N.} and Mellink, {Clemens H. M.} and {van der Kevie-Kersemaekers}, Anne-Marie and Evers, {Ludo M.} and Kim Heezen and Kolijn, {P. Martijn} and Mook, {Olaf R. F.} and Motazacker, {M. Mahdi} and Kazem Nasserinejad and S. Kersting and Westerweel, {Peter E.} and Niemann, {Carsten U.} and Kater, {Arnon P.} and Langerak, {Anton W.} and Mark-David Levin",

note = "Funding Information: SK has received personal fees from Janssen, AbbVie, Novartis, Gilead, and Celgene; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. CUN received research funding and/or consultancy fees from Abbvie, AstraZeneca, Roche, Janssen, CSL Behring, Takeda, and Octapharma. APK has received personal fees from AbbVie, LAVA, Genmab, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb; and research funding from AbbVie, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb. AWL has received research support via an unrestricted grant from Roche-Genentech and a speaker-fee from Janssen. M-DL has received personal fees from AbbVie, Janssen, and Roche; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. All other authors declare no competing interests. Funding Information: The HOVON-139/GIVE trial was funded by F Hoffmann-La Roche (ML29995), who had the opportunity to review and comment on this paper. The HOVON-141/VIsion trial was supported by AbbVie and Janssen/Pharmacyclics, who had the opportunity to review and comment on this paper. In addition, the HOVON-141/VIsion trial was funded by the Novo Nordisk Foundation grant NNF160C0019302.",

year = "2022",

month = jul,

day = "1",

doi = "https://doi.org/10.1038/s41375-022-01600-6",

language = "English",

volume = "36",

pages = "1935--1938",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "7",

}

Hengeveld, PJ, Ertem, YE, Dubois, JMN, Mellink, CHM , van der Kevie-Kersemaekers, A-M, Evers, LM, Heezen, K, Kolijn, PM, Mook, ORF , Motazacker, MM, Nasserinejad, K, Kersting, S, Westerweel, PE, Niemann, CU, Kater, AP, Langerak, AW & Levin, M-D 2022, 'Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110', Leukemia, vol. 36, no. 7, pp. 1935-1938. https://doi.org/10.1038/s41375-022-01600-6

TY - JOUR

T1 - Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

AU - Hengeveld, Paul J.

AU - Ertem, Y. Emre

AU - Dubois, Julie M. N.

AU - Mellink, Clemens H. M.

AU - van der Kevie-Kersemaekers, Anne-Marie

AU - Evers, Ludo M.

AU - Heezen, Kim

AU - Kolijn, P. Martijn

AU - Mook, Olaf R. F.

AU - Motazacker, M. Mahdi

AU - Nasserinejad, Kazem

AU - Kersting, S.

AU - Westerweel, Peter E.

AU - Niemann, Carsten U.

AU - Kater, Arnon P.

AU - Langerak, Anton W.

AU - Levin, Mark-David

N1 - Funding Information: SK has received personal fees from Janssen, AbbVie, Novartis, Gilead, and Celgene; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. CUN received research funding and/or consultancy fees from Abbvie, AstraZeneca, Roche, Janssen, CSL Behring, Takeda, and Octapharma. APK has received personal fees from AbbVie, LAVA, Genmab, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb; and research funding from AbbVie, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb. AWL has received research support via an unrestricted grant from Roche-Genentech and a speaker-fee from Janssen. M-DL has received personal fees from AbbVie, Janssen, and Roche; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. All other authors declare no competing interests. Funding Information: The HOVON-139/GIVE trial was funded by F Hoffmann-La Roche (ML29995), who had the opportunity to review and comment on this paper. The HOVON-141/VIsion trial was supported by AbbVie and Janssen/Pharmacyclics, who had the opportunity to review and comment on this paper. In addition, the HOVON-141/VIsion trial was funded by the Novo Nordisk Foundation grant NNF160C0019302.

PY - 2022/7/1

Y1 - 2022/7/1

UR - http://www.scopus.com/inward/record.url?scp=85130283203&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41375-022-01600-6

DO - https://doi.org/10.1038/s41375-022-01600-6

M3 - Article

C2 - 35585140

SN - 0887-6924

VL - 36

SP - 1935

EP - 1938

JO - Leukemia

JF - Leukemia

IS - 7

ER -

Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

Access to Document

Other files and links

Cite this